Dr. Roddy Carter Named President and CEO of WellGen, Inc.

WellGen, Inc., today announced that Dr. Roderick (Roddy) Carter, M.D., M.Sc., has been appointed President and Chief Executive Officer.

Dr. Carter, 45, takes over from Robert J. Bertoldi, who was serving as interim Chief Executive Officer. Mr. Bertoldi will continue in his WellGen Board position and as President and Chief Financial Officer of Amphion Innovations plc (LSE: AMP), a significant shareholder in WellGen.

Mr. Bertoldi said, “Roddy Carter’s range of experience, along with his significant achievements in medicine, research, and pharmaceutical development and commercialization, fits perfectly with WellGen as we develop medical foods using our proprietary Alignomx™ research model. We are very pleased to have him join the team as the company rolls out its first commercial products and continues its clinical research to develop additional products.”

Since 2008, Dr. Carter has been principal at Aquila Life Sciences LLC, a consulting firm focusing on pharmaceutical development and commercialization. Before that he was Vice President of Clinical Development (2007 – 2008) at Reliant Pharmaceuticals USA, which today is a wholly owned subsidiary of GlaxoSmithKline plc. Earlier in his career, Dr. Carter was a Senior Medical Director at Pfizer, Inc. (2004-2006), where he led teams for the development and commercialization of Lipitor™ and Viagra™, among others. Prior to that, he worked as director of marketing at Merck and Co.’s Europe, Middle East, and Africa (EMEA) division, and at Merck Sharpe and Dohme (MSD) in South Africa.

Before entering the pharmaceutical industry, Dr. Carter established the Centre for the Study of Exercise, Nutrition and Muscle Science at the University of the Witwatersrand, Johannesburg, South Africa. This academic leadership position followed Dr. Carter’s early professional years as a family practitioner.

“I am excited to be part of WellGen,” said Dr. Carter. “The market is now ready, as never before, for the introduction of natural products that provide therapeutic benefits based on their impact on gene expression. I look forward to leading the team as we develop WellGen’s pipeline of products and achieve success in the emerging field of medical foods.”

Dr. Carter received his medical degree from the University of the Witwatersrand and then a Master of Science degree in Sports Medicine from Trinity College, Dublin.

About Amphion:

Amphion Innovations (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in eight Partner Companies and two specialized entities, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. On the web: www.amphionplc.com

About WellGen

WellGen, Inc., based in North Brunswick, N.J., is a life science company at the crossroads of foods and pharmaceuticals. Using the science of nutrigenomics, the company has developed Alignomx™, a proprietary bioinformatics model that uses gene expression data to determine optimal therapeutic niches for WellGen’s pipeline of proprietary natural products. Through its in-house expertise in nutrigenomics and natural product chemistry, WellGen is developing proprietary medical foods and has additionally identified several opportunities in the functional food and beverage and dietary supplement markets. Please visit our website at www.wellgen.com for more information.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.